Intrapleural use of tissue plasminogen activator and DNase in pleural infection
BACKGROUND: More than 30% of patients with pleural infection either die or require surgery. Drainage of infected fluid is key to successful treatment, but intrapleural fibrinolytic therapy did not improve outcomes in an earlier, large, randomized trial. METHODS: We conducted a blinded, 2-by-2 factor...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1797063416328749056 |
|---|---|
| author | Rahman, N Maskell, N West, A Teoh, R Arnold, A Mackinlay, C Peckham, D Davies, C Ali, N Kinnear, W Bentley, A Kahan, B Wrightson, J Davies, H Hooper, C Lee, Y Hedley, E Crosthwaite, N Choo, L Helm, E Gleeson, F Nunn, A Davies, R |
| author_facet | Rahman, N Maskell, N West, A Teoh, R Arnold, A Mackinlay, C Peckham, D Davies, C Ali, N Kinnear, W Bentley, A Kahan, B Wrightson, J Davies, H Hooper, C Lee, Y Hedley, E Crosthwaite, N Choo, L Helm, E Gleeson, F Nunn, A Davies, R |
| author_sort | Rahman, N |
| collection | OXFORD |
| description | BACKGROUND: More than 30% of patients with pleural infection either die or require surgery. Drainage of infected fluid is key to successful treatment, but intrapleural fibrinolytic therapy did not improve outcomes in an earlier, large, randomized trial. METHODS: We conducted a blinded, 2-by-2 factorial trial in which 210 patients with pleural infection were randomly assigned to receive one of four study treatments for 3 days: double placebo, intrapleural tissue plasminogen activator (t-PA) and DNase, t-PA and placebo, or DNase and placebo. The primary outcome was the change in pleural opacity, measured as the percentage of the hemithorax occupied by effusion, on chest radiography on day 7 as compared with day 1. Secondary outcomes included referral for surgery, duration of hospital stay, and adverse events. RESULTS: The mean (±SD) change in pleural opacity was greater in the t-PA-DNase group thanin the placebo group (-29.5±23.3% vs. -17.2±19.6%; difference, -7.9%; 95% confidenceinterval [CI], -13.4 to -2.4; P = 0.005); the change observed with t-PA alone and with DNase alone (-17.2±24.3 and -14.7±16.4%, respectively) was not significantly differentfrom that observed with placebo. The frequency of surgical referral at 3 months was lower in the t-PA-DNase group than in the placebo group (2 of 48 patients [4%] vs. 8 of 51 patients [16%]; odds ratio for surgical referral, 0.17; 95% CI, 0.03 to 0.87; P = 0.03) but was greater in the DNase group (18 of 46 patients [39%]) than in the placebo group (odds ratio, 3.56; 95% CI, 1.30 to 9.75; P = 0.01). Combined t-PA-DNase therapy was associated with a reduction in the hospital stay, as compared with placebo (difference, -6.7 days; 95% CI, -12.0 to -1.9; P = 0.006); the hospital stay with either agent alone was not significantly different from that with placebo. The frequency of adverse events did not differ significantly among the groups. CONCLUSIONS: Intrapleural t-PA-DNase therapy improved fluid drainage in patients with pleural infection and reduced the frequency of surgical referral and the duration of the hospital stay. Treatment with DNase alone or t-PA alone was ineffective. (Funded by an unrestricted educational grant to the University of Oxford from Roche UK and by others; Current Controlled Trials number, ISRCTN57454527.) Copyright © 2011 Massachusetts Medical Society. |
| first_indexed | 2024-03-06T20:59:32Z |
| format | Journal article |
| id | oxford-uuid:3a68b16d-d0c1-4d9d-98fb-aa7a661c8a24 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:59:32Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:3a68b16d-d0c1-4d9d-98fb-aa7a661c8a242022-03-26T14:01:31ZIntrapleural use of tissue plasminogen activator and DNase in pleural infectionJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3a68b16d-d0c1-4d9d-98fb-aa7a661c8a24EnglishSymplectic Elements at Oxford2011Rahman, NMaskell, NWest, ATeoh, RArnold, AMackinlay, CPeckham, DDavies, CAli, NKinnear, WBentley, AKahan, BWrightson, JDavies, HHooper, CLee, YHedley, ECrosthwaite, NChoo, LHelm, EGleeson, FNunn, ADavies, RBACKGROUND: More than 30% of patients with pleural infection either die or require surgery. Drainage of infected fluid is key to successful treatment, but intrapleural fibrinolytic therapy did not improve outcomes in an earlier, large, randomized trial. METHODS: We conducted a blinded, 2-by-2 factorial trial in which 210 patients with pleural infection were randomly assigned to receive one of four study treatments for 3 days: double placebo, intrapleural tissue plasminogen activator (t-PA) and DNase, t-PA and placebo, or DNase and placebo. The primary outcome was the change in pleural opacity, measured as the percentage of the hemithorax occupied by effusion, on chest radiography on day 7 as compared with day 1. Secondary outcomes included referral for surgery, duration of hospital stay, and adverse events. RESULTS: The mean (±SD) change in pleural opacity was greater in the t-PA-DNase group thanin the placebo group (-29.5±23.3% vs. -17.2±19.6%; difference, -7.9%; 95% confidenceinterval [CI], -13.4 to -2.4; P = 0.005); the change observed with t-PA alone and with DNase alone (-17.2±24.3 and -14.7±16.4%, respectively) was not significantly differentfrom that observed with placebo. The frequency of surgical referral at 3 months was lower in the t-PA-DNase group than in the placebo group (2 of 48 patients [4%] vs. 8 of 51 patients [16%]; odds ratio for surgical referral, 0.17; 95% CI, 0.03 to 0.87; P = 0.03) but was greater in the DNase group (18 of 46 patients [39%]) than in the placebo group (odds ratio, 3.56; 95% CI, 1.30 to 9.75; P = 0.01). Combined t-PA-DNase therapy was associated with a reduction in the hospital stay, as compared with placebo (difference, -6.7 days; 95% CI, -12.0 to -1.9; P = 0.006); the hospital stay with either agent alone was not significantly different from that with placebo. The frequency of adverse events did not differ significantly among the groups. CONCLUSIONS: Intrapleural t-PA-DNase therapy improved fluid drainage in patients with pleural infection and reduced the frequency of surgical referral and the duration of the hospital stay. Treatment with DNase alone or t-PA alone was ineffective. (Funded by an unrestricted educational grant to the University of Oxford from Roche UK and by others; Current Controlled Trials number, ISRCTN57454527.) Copyright © 2011 Massachusetts Medical Society. |
| spellingShingle | Rahman, N Maskell, N West, A Teoh, R Arnold, A Mackinlay, C Peckham, D Davies, C Ali, N Kinnear, W Bentley, A Kahan, B Wrightson, J Davies, H Hooper, C Lee, Y Hedley, E Crosthwaite, N Choo, L Helm, E Gleeson, F Nunn, A Davies, R Intrapleural use of tissue plasminogen activator and DNase in pleural infection |
| title | Intrapleural use of tissue plasminogen activator and DNase in pleural infection |
| title_full | Intrapleural use of tissue plasminogen activator and DNase in pleural infection |
| title_fullStr | Intrapleural use of tissue plasminogen activator and DNase in pleural infection |
| title_full_unstemmed | Intrapleural use of tissue plasminogen activator and DNase in pleural infection |
| title_short | Intrapleural use of tissue plasminogen activator and DNase in pleural infection |
| title_sort | intrapleural use of tissue plasminogen activator and dnase in pleural infection |
| work_keys_str_mv | AT rahmann intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT maskelln intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT westa intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT teohr intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT arnolda intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT mackinlayc intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT peckhamd intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT daviesc intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT alin intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT kinnearw intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT bentleya intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT kahanb intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT wrightsonj intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT daviesh intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT hooperc intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT leey intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT hedleye intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT crosthwaiten intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT chool intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT helme intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT gleesonf intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT nunna intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection AT daviesr intrapleuraluseoftissueplasminogenactivatoranddnaseinpleuralinfection |